Explainer · July 10, 2026
By Peppies · July 10, 2026 · 2 min read
A plain-English map of the road from 'an advisory committee is looking at peptides' to 'you can legally get one.'
Most coverage collapses a long process into one headline. Here's the actual road.
September 2023: the FDA placed a group of peptides, including BPC-157, in "Category 2" of its interim compounding list - the bucket for substances that raise significant safety questions. In plain terms, they couldn't be legally compounded.
April 2026: a reshaped FDA removed twelve peptides from Category 2 and referred seven of them to the advisory committee. Removal from Category 2 is not approval - it moves them into review.
July 23-24, 2026: the committee hears evidence and votes a recommendation. Advisory and non-binding.
After that: the FDA decides whether to open formal rulemaking - a proposed rule, a public comment period, and a final rule. That later comment window is the one where an ordinary person's comment carries legal weight, and most people never hear it open. [1]
So if you take one thing away: the July vote is a signal, not a finish line. The decision that actually changes access comes later - see the full timeline, and we'll tell you the moment that window opens.
